Meeting
2022 ASCO Annual Meeting
Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.
Authors
Arun Azad
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Arun Azad , Taro Iguchi , Boris Alekseev , Neal D. Shore , Jennifer Sugg , Gabriel P. Haas , Michele Wozniak , Thomas O'Brien , Douglas Laird , Arnulf Stenzl , Andrew J. Armstrong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT02677896
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5074)
DOI
10.1200/JCO.2022.40.16_suppl.5074
Abstract #
5074
Poster Bd #
257
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.
First Author: Andrew J. Armstrong
Poster
2022 ASCO Annual Meeting
![The association of germline<em> HSD3B1</em> genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].](https://d201v5jt9ylckg.cloudfront.net/288/14370/212152/212152_A1803_poster_pv.jpg)
The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
First Author: Nima Sharifi
Poster
2022 ASCO Annual Meeting
Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analysis of ARCHES.
First Author: Andrew J. Armstrong
Poster
2021 Genitourinary Cancers Symposium
Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.
First Author: Arun Azad